These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3567309)

  • 1. A dose-response model incorporating nonlinear kinetics.
    Van Ryzin J; Rai K
    Biometrics; 1987 Mar; 43(1):95-105. PubMed ID: 3567309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A generalized multihit dose-response model for low-dose extrapolation.
    Rai K; Van Ryzin J
    Biometrics; 1981 Jun; 37(2):341-52. PubMed ID: 7272419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confidence intervals and test of hypotheses concerning dose response relations inferred from animal carcinogenicity data.
    Crump KS; Guess HA; Deal KL
    Biometrics; 1977 Sep; 33(3):437-51. PubMed ID: 911968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-response model for teratological experiments involving quantal responses.
    Rai K; Van Ryzin J
    Biometrics; 1985 Mar; 41(1):1-9. PubMed ID: 4005367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An improved procedure for low-dose carcinogenic risk assessment from animal data.
    Crump KS
    J Environ Pathol Toxicol Oncol; 1984 Jul; 5(4-5):339-48. PubMed ID: 6520736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of non-linear (dose-dependent) pharmacokinetics in hazard assessment.
    Watanabe PG; Young JD; Gehring PJ
    J Environ Pathol Toxicol; 1977; 1(2):147-59. PubMed ID: 553128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
    Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
    Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state solutions to PBPK models and their applications to risk assessment I: Route-to-route extrapolation of volatile chemicals.
    Chiu WA; White P
    Risk Anal; 2006 Jun; 26(3):769-80. PubMed ID: 16834633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A statistical test of compatibility of data sets to a common dose-response model.
    Stiteler WM; Knauf LA; Hertzberg RC; Schoeny RS
    Regul Toxicol Pharmacol; 1993 Dec; 18(3):392-402. PubMed ID: 8128001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating additional biological phenomena into two-stage cancer models.
    Sielken RL; Bretzlaff RS; Stevenson DE
    Prog Clin Biol Res; 1994; 387():237-60. PubMed ID: 7972250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer dose--response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity.
    Kirman CR; Gargas ML; Marsh GM; Strother DE; Klaunig JE; Collins JJ; Deskin R
    Regul Toxicol Pharmacol; 2005 Oct; 43(1):85-103. PubMed ID: 16099568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The assessment of low-dose carcinogenicity.
    Armitage P
    Biometrics; 1982 Mar; 38 Suppl():119-39. PubMed ID: 7046818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs.
    Gardner SN
    Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linear interpolation algorithm for low dose risk assessment of toxic substances.
    Gaylor DW; Kodell RL
    J Environ Pathol Toxicol; 1980 Nov; 4(5-6):305-12. PubMed ID: 7217854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determining the values of threshold levels of the effects of harmful substances].
    Novikov SM; Levchenko NI; Me'lnikova NN; Fursova TN
    Gig Sanit; 1989 Sep; (9):46-9. PubMed ID: 2591784
    [No Abstract]   [Full Text] [Related]  

  • 16. Threshold dose-response models in toxicology.
    Cox C
    Biometrics; 1987 Sep; 43(3):511-23. PubMed ID: 3663815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the use of historical control data to estimate dose response trends in quantal bioassay.
    Prentice RL; Smythe RT; Krewski D; Mason M
    Biometrics; 1992 Jun; 48(2):459-78. PubMed ID: 1637972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
    Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
    Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonlinearity and thresholds in dose-response relationships for carcinogenicity due to sampling variation, logarithmic dose scaling, or small differences in individual susceptibility.
    Lutz WK; Gaylor DW; Conolly RB; Lutz RW
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):565-9. PubMed ID: 15982698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum likelihood estimation for cytogenetic dose-response curves.
    Frome EL; DuFrain RJ
    Biometrics; 1986 Mar; 42(1):73-84. PubMed ID: 3719064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.